Genomma Lab Internacional SAB de CV (GNMLF) Price & Analysis

Genomma Lab Internacional SAB de CV Class B released its earnings results on Oct 21, 2026. The company reported $0.027 earnings per share for the quarter, beating the consensus estimate of $0.021 by $0.006.

Is Genomma Lab Internacional SAB de CV Class B overvalued?

According to Wall Street analysts Genomma Lab Internacional SAB de CV Class B’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Genomma Lab Internacional SAB de CV Class B pay dividends?

Genomma Lab Internacional SAB de CV Class B pays a Quarterly dividend of $0.011 which represents an annual dividend yield of 5.44%. See more information on Genomma Lab Internacional SAB de CV Class B dividends here

What is Genomma Lab Internacional SAB de CV Class B’s EPS estimate?

Genomma Lab Internacional SAB de CV Class B’s EPS estimate is 0.02.

How many shares outstanding does Genomma Lab Internacional SAB de CV Class B have?

Genomma Lab Internacional SAB de CV Class B has 1,000,000,000 shares outstanding.

What happened to Genomma Lab Internacional SAB de CV Class B’s price movement after its last earnings report?

Genomma Lab Internacional SAB de CV Class B reported an EPS of $0.027 in its last earnings report, beating expectations of $0.021. Following the earnings report the stock price went up 1.816%.

Which hedge fund is a major shareholder of Genomma Lab Internacional SAB de CV Class B?

Currently, no hedge funds are holding shares in GNMLF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Genomma Lab Internacional SAB de CV Class B

Genomma Lab Internacional, S.A.B. de C.V., along with its subsidiary companies, specializes in the formulation, promotion, and worldwide distribution of non-prescription pharmaceuticals and personal hygiene products. The firm's extensive product range covers areas such as skincare, general health and wellness, haircare, pain management, cold and flu remedies, gastrointestinal treatments, sexual health, antiperspirant deodorants, hand sanitizers, rehydration drinks, and shaving essentials. It also provides analgesics, antifungal solutions, and hemorrhoid treatments. These items are sold under numerous recognized brands, including Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, among others. Incorporated in 1996, Genomma Lab Internacional, S.A.B. de C.V. is headquartered in Mexico City, Mexico.

Genomma Lab Internacional SAB de CV (GNMLF) Earnings & Revenues

Historic Earnings Reports

GNMLF Earnings Call

Q3 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed a cautiously optimistic recovery narrative. Mexico sellout, market share, innovation, Latin America growth, cash flow, liquidity, and debt maturity improvements were significant positives, while the United States remained difficult, margins contracted, working capital increased, Brazil faced tax-reform-related inventory pressure, and part of net income growth came from a nonrecurring foreign exchange gain. Management characterized the quarter as mixed but emphasized that the recovery plan was working and that sellout improvement was underway.View all GNMLF earnings summaries